Caricamento...
Metastatic melanoma: treatment and survival in the US after the introduction of ipilimumab and vemurafenib
INTRODUCTION: 5- year survival of metastatic melanoma is < 18%. Historically, treatment options were limited; in 2011 two new agents were approved. METHODS: A random sample (n=520) of metastatic melanoma patients diagnosed in 2011 and reported to population-based registries in the U.S. had their...
Salvato in:
| Pubblicato in: | Oncol Res Treat |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2017
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5383086/ https://ncbi.nlm.nih.gov/pubmed/28376479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000456014 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|